Castor vs the COVID-19 virus

28 April 2021

Castor Provides Continued Support to the World Health Organization, Powering the World’s Largest Adaptive COVID-19 Trial

Castor announced continued support for the WHO Solidarity trial, the world’s largest adaptive COVID-19 trial.

22 April 2021

Introducing Castor Connect

Watch this webinar for tips on how to ensure research continuity during COVID-19 by running your trial with a more decentralized approach.

12 October 2020

Research Continuity During COVID-19

Watch this webinar for tips on how to ensure research continuity during COVID-19 by running your trial with…

5 October 2020

Common shortcomings of clinical research data for PMCF

The following is an excerpt from our free whitepaper ‘Satisfying PMCF requirements by utilizing IIS data’. Click here…

White papers & guides

8 September 2020

Guide to eConsent Readiness in the US, Europe, and Israel

eConsent regulations vary widely across the world. Download this guide for an overview of the current regulatory situation in nine countries.

7 September 2020

eConsent – The Enrollment Solution for Decentralized Trials

Join this webinar to understand how eConsent works, where it falls in the regulatory guidelines & see a practical demonstration of eConsent software.

31 August 2020

Castor Announces Partnership With Click Therapeutics to Support Decentralized Clinical Trials

Hoboken, New Jersey: September 2, 2020: Castor, a leading provider of clinical trial technology that automates the research…

19 August 2020

Castor Raises a $12M Series A to Further Their Support for COVID-19 Research

With 4,000 live studies and 2M enrolled patients across 90 countries, Castor will use the funding to further…

14 August 2020

An Expert Panel on Decentralized and Hybrid Trials, Pre and Post COVID-19

The world may have changed seemingly overnight, but clinical research and medical innovation must continue now more than…

29 July 2020

What Will Trial Enrollment & Engagement Look Like in a Socially-Distanced World?

When the COVID-19 pandemic began, the industry needed to focus immediately on research continuity and determine how to mitigate the impact on clinical trials while protecting participant safety.